As compared to CKD without treatment, 12 months of SGLT2 inhibition was associated with a 5 mmHg lower systolic BP (Figure 8), relatively similar GFR, 18% reduction in dead nephrons, and 5% reduction in albuminuria (Figure 8). This evidence concerns the gene SLC5A2 and chronic kidney disease.